Date: 2017-04-27
Type of information: Research agreement
Compound:
Company: Takeda Pharmaceutical (Japan) Harrington Discovery Institute (USA - OH)
Therapeutic area: Rare diseases
Type agreement: research - R&D
Action mechanism:
Disease:
Details:
- • On April 27, 2017, Takeda Pharmaceutical and Harrington Discovery Institute at University Hospitals in Cleveland have announced a multi-year collaboration to accelerate breakthrough therapeutic discoveries in rare diseases.
- A first of a kind partnership for Harrington Discovery Institute with a major pharmaceutical company, this collaboration with Takeda will build on Harrington Discovery Institute’s established operating model to create a new program specifically for the advancement of medicines for rare diseases. At the same time, this collaboration will complement Takeda’s strategic R&D focus in its therapeutic areas of oncology, gastroenterology and central nervous
system disorders.
- The new Harrington program will focus on M.D. and Ph.D. researchers from across the United States, developing disruptive and transformative research, which shows promise for translation into novel treatments. Researchers in the new program will have access to grant funding from the Harrington Discovery Institute and hands-on drug development capability and project management from experts in its Innovation Support Center. In addition to those resources, researchers will also have access to Takeda’s internal research and development experts.
Financial terms:
Latest news:
Is general: Yes
